China Meheco Group Co

China Meheco Group Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co (600056.SS) as of Oct 22, 2026 is 230.92 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 120.79 % — a change of 91.17% (higher).

FCF Conversion

230.92 %

YoY

91.17%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co is 2025 230.92 % . FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co was 2024 120.79 % . It decreases by 91.17% higher compared to the previous year.

The China Meheco Group Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-16.94 CNY
Jan 1, 2019
-34.05 CNY
Jan 1, 2020
94.73 CNY
Jan 1, 2021
-21.28 CNY
Jan 1, 2022
192.62 CNY
Jan 1, 2023
47.38 CNY
Jan 1, 2024
120.79 CNY
Jan 1, 2025
230.92 CNY
The China Meheco Group Co FCF Conversion history
YEARFCF ConversionYoY
230.92 %+91.17%
120.79 %+154.96%
47.38 %-75.40%
192.62 %-1,004.95%
-21.28 %-122.47%
94.73 %-378.20%
-34.05 %+101.01%
-16.94 %-155.55%
30.50 %-65.94%
89.54 %-38.47%
145.51 %-10.84%
163.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

China Meheco Group Co Stock analysis

What does China Meheco Group Co do? China Meheco Group Co., Ltd. generates revenue through its Industrial Pharmaceutical segment, which manufactures and distributes chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces. The Commercial Pharmaceutical segment focuses on wholesale and distribution of pharmaceuticals and medical devices. The Trading segment handles international exporting and medical resourcing introduction. The company serves healthcare providers, hospitals, and pharmacies through its wholesale operations, targeting the pharmaceutical and medical device markets in China and internationally. The Industrial Pharmaceutical segment produces chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces for distribution. The Commercial Pharmaceutical segment supplies pharmaceuticals and medical devices to healthcare institutions and retailers. The Trading segment facilitates international exports of pharmaceutical products and introduces medical resources globally, catering to global healthcare markets. China Meheco's revenue streams are derived from the sale of pharmaceutical products across its three segments. The Industrial segment manufactures and sells chemical and traditional Chinese medicine products, while the Commercial segment distributes these products through wholesale channels. The Trading segment earns from exporting pharmaceuticals and managing international medical resource procurement for global clients. China Meheco Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about China Meheco Group Co stock

FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co is 230.92 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co changed from 120.79 % to 230.92 %, representing a 91.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) China Meheco Group Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s China Meheco Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — China Meheco Group Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — China Meheco Group Co